Ignite Creation Date:
2024-05-06 @ 1:03 AM
Last Modification Date:
2024-10-26 @ 10:58 AM
Study NCT ID:
NCT01725269
Status:
TERMINATED
Last Update Posted:
2014-04-09
First Post:
2012-11-08
Brief Title:
Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
Sponsor:
Aires Pharmaceuticals Inc
Organization:
Aires Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Multicenter Open-Label Study to Evaluate the IntermediateLong Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Status:
TERMINATED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated early dt acquisition of Sponsor and change in corporate priorities
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The AIR001-CS05 study evaluated the safety and efficacy effectiveness of AIR001 over 16 weeks in subjects who have PAH The purpose of the AIR001-CS06 study is to evaluate the intermediate long-term safety of AIR001 in subjects who have completed the AIR001-CS05 study Assessments to evaluate the effectiveness of the study drug will include measurements of exercise ability and evaluations of PAH disease symptoms
Detailed Description:
The primary objective of this study is to evaluate the intermediatelong-term safety of inhaled nebulized AIR001 administered according to 3 treatment arms 80 milligrams mg 4 times daily 46 mg 4 times daily or 80 mg once daily in subjects with World Health Organization WHO Group 1 Pulmonary Arterial Hypertension PAH who have completed the 16-week AIR001-CS05 study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None